Children’s National experts showcase sickle cell disease research

illustration of sickled blood cellsAndrew Campbell, M.D., director of the Comprehensive Sickle Cell Disease program, assessed the lifetime value of cell and gene therapy (CGTS) through a case study at The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting.

Dr. Campbell and other Children’s National researchers will be presenting again at the Foundation for Sickle Cell Disease Research’s (FSCDR) Annual Sickle Cell Disease Research and Educational Symposium, June 7-9, 2024. The symposium includes more than 500 leading researchers, physicians, clinicians and social workers from all over the world.

Here’s a look at the presentations from Children’s National:

DayTimePresenter(s)Title
Sunday, June 9, 20248:00 AM – 9:15 AMAndrew Campbell, M.D.Update on Sickle Cell Legislation in the US

 

Sunday, June 9, 20243:00 PM – 3:15 PMAndrew Campbell, M.D., Deepika Darbari, M.D., and Regine Hyppolite, MSADiagnostic Potential of Platelet-Neutrophil Ratio (PNR) for Stroke Risk in SCD Children

 

Sunday, June 9, 20243:15 PM – 3:30 PM

 

Andrew Campbell, M.D.A Pilot Study to Increase Naloxone Education and Prescriptions in Sickle Cell Clinics

 

Sunday, June 9, 20244:00 PM – 4:15 PMSteven Hardy, Ph.D.Correlation Between VOC and Cognitive Function Using The NIH ToolBox in SCD
Sunday, June 9, 20244:15 PM – 4:30 PM

 

 

Andrew Campbell, M.D., Deepika Darbari, M.D., and Regine Hyppolite, MSAPlatelet to neutrophil ratio as a novel marker for monitoring SCD patients on hydroxyurea